PubMed Health⌕ Search

PubMed · 10901834

[French version of the video structured interview designed for type A behavior pattern assessment].

Abstract

The current controversy on the predictive value of the Type A Behavior Pattern (TABP) as a coronary risk factor brought into a reconsideration of the assessment methods of this pattern. The Video Structured Interview (VSI) is a scoring method of TABP by a trained investigator, consisting of a rating scale based both on the content of the answers and on the psychomotor signs, with regard to the two main components of the TABP: sense of time urgency and hostility. The VSI appears a more objective instrument than self-assessment questionnaires, avoiding the bias of denial, a coping mechanism widely used by type A subjects. The VSI proved more sensitive and more specific than the self-assessment methods or the structured interview (SI), the initial instrument aimed to assess TABP among coronary risk patients in american populations. We here present the french version of the VSI, the technical modes of the interview and the principles of this scoring method, in order to introduce in France its use in further studies related with coronary risk factors.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

K Lahlou, P Aloupis, L Powell, S M Consoli. [French version of the video structured interview designed for type A behavior pattern assessment].. https://pubmed.ncbi.nlm.nih.gov/10901834/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.

The peroxisome proliferator-activated receptor (PPAR) family of genes plays a major role in metabolic regulation. Unfortunately, the results of two recent, large event trials of PPAR agonists have been mixed. High rates of crossover to statin use confound the interpretation of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which found a less than expected reduction in coronary and stroke events with fenofibrate. Of concern, nonsignificant increases in coronary and sudden deaths, thrombotic events, and pancreatitis occurred in the fenofibrate group. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROACTIVE) also found a reduction in coronary and stroke events with pioglitazone compared with placebo in a population with diabetes and cardiovascular disease, but this benefit was counterbalanced by an increase in congestive heart failure as well as symptomatic edema. Further research is needed to determine the role of PPAR agonists in the prevention of cardiovascular disease.

Coronary Disease↗

Depressive symptoms and sex affect completion rates and clinical outcomes in cardiac rehabilitation.

Symptoms of depression are often seen in patients with coronary heart disease. Symptoms appear more commonly in women and are negatively associated with measures of cardiovascular health. Using multiple logistic regression analyses, the authors evaluated the independent effects of depression (as measured by the Beck Depression Inventory [BDI-II]) and sex on cardiac rehabilitation (CR) completion. In addition, in those who completed CR, the authors evaluated whether depressive symptoms and sex affected clinical outcomes. Women as well as participants with enrollment BDI-II scores > or =14 had significantly higher rates of CR noncompletion. Patients with BDI-II scores > or =14 who completed CR achieved significant improvements in lipid profile, body mass index, and exercise capacity regardless of sex. Women and individuals with BDI-II scores > or =14 are at risk for CR noncompletion and should be encouraged to complete CR, because cardiovascular benefits comparable to those seen in men and individuals with low BDI-II scores were achieved when these patients completed the CR program.

Coronary Disease↗